FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887473668> ?p ?o ?g. }

• W2887473668 endingPage "5706" @default.
• W2887473668 startingPage "5706" @default.
• W2887473668 abstract "Abstract Background: Tumor mutational burden (TMB) has emerged as a new biomarker for response to checkpoint inhibitor immunotherapy. Recently, we described a novel assay to calculate TMB from the circulating tumor DNA (ctDNA) in the blood (bTMB) and demonstrated validation to support its application in a prospective phase III trial in 1L NSCLC comparing the anti-PD-L1 agent, atezolizumab, against standard of care chemotherapy. Herein, we demonstrate clinical utility of the bTMB assay across a retrospective study of 794 NSCLC patients from two randomized clinical trials evaluating progression free survival (PFS) and overall survival (OS) between atezolizumab and chemotherapy. Furthermore, we compare TMB between tissue and blood, and evaluate variant-level concordance between the bTMB assay and the CLIA-validated ctDNA assay, FoundationACT (FACT). Methods: Cell free DNA (cfDNA) from plasma was isolated from retrospective clinical samples. The bTMB assay delivered a count of somatic base substitutions in the ctDNA down to 0.5% allele frequency across 394 genes from as little as 1% tumor content, yielding a bTMB score. Tissue TMB was evaluated from formalin-fixed, paraffin embedded specimens using the FoundationOne assay. Results: Patients with bTMB ≥14 mut/Mb were considered high, and demonstrated significant enrichment for both PFS and OS in the phase II POPLAR study evaluating atezolizumab vs. chemotherapy (PFS HR = 0.57, OS HR = 0.56, n=211). Survival results were validated in the larger phase III study, OAK (PFS HR = 0.65, OS HR = 0.64, n=583). Significant enrichment in PFS was observed between bTMB-high and non-high patients receiving atezolizumab, however this effect was not observed for patients receiving chemotherapy. Amongst 259 patients with blood and tissue TMB, overall and positive percent agreement (PPA) in the TMB categorical result were 81.5% and 63.6%, respectively. When bTMB was restricted to the 62 gene FACT assay, the PPA dropped to 17.0%, suggesting a sufficiently sized panel is required to sensitively identify patients with high TMB. When samples were TMB-high in blood, the median percent overlap of TMB variants between blood and tissue was 70%. Blood samples tested in both the bTMB and FACT assays revealed that 93% of variants were detected in both assays across overlapping regions, with ≥99% of variants detected in both platforms with variant allele frequency ≥1.0%. Conclusions: The bTMB assay is analytically validated for high accuracy and precision, and demonstrates a high degree of variant level concordance with the FACT assay. High bTMB is significantly associated with improved survival to atezolizumab vs. chemotherapy in 2L NSCLC, and the survival benefit is specific to atezolizumab and not prognostic. Finally, TMB between blood and tissue is correlated and largely explained by overlapping variants present in both sample types. Citation Format: David Fabrizio, Daniel Lieber, Christine Malboeuf, Jacob Silterra, Emily White, Michael Coyne, Tina Brennan, Jie Ma, Mark Kennedy, Erica Schleifman, Sarah Paul, Yan Li, David Shames, Craig Cummings, Eric Peters, Marcin Kowanetz, Doron Lipson, Geoff Otto. A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5706." @default.
• W2887473668 created "2018-08-22" @default.
• W2887473668 creator A5000413092 @default.
• W2887473668 creator A5001204975 @default.
• W2887473668 creator A5001816288 @default.
• W2887473668 creator A5002641296 @default.
• W2887473668 creator A5007455008 @default.
• W2887473668 creator A5011484481 @default.
• W2887473668 creator A5016568716 @default.
• W2887473668 creator A5028478747 @default.
• W2887473668 creator A5029183165 @default.
• W2887473668 creator A5038805449 @default.
• W2887473668 creator A5040846333 @default.
• W2887473668 creator A5049192558 @default.
• W2887473668 creator A5052880029 @default.
• W2887473668 creator A5064263842 @default.
• W2887473668 creator A5066068230 @default.
• W2887473668 creator A5071586460 @default.
• W2887473668 creator A5084619380 @default.
• W2887473668 creator A5088627335 @default.
• W2887473668 date "2018-07-01" @default.
• W2887473668 modified "2023-10-18" @default.
• W2887473668 title "Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab" @default.
• W2887473668 doi "https://doi.org/10.1158/1538-7445.am2018-5706" @default.
• W2887473668 hasPublicationYear "2018" @default.
• W2887473668 type Work @default.
• W2887473668 sameAs 2887473668 @default.
• W2887473668 citedByCount "20" @default.
• W2887473668 countsByYear W28874736682018 @default.
• W2887473668 countsByYear W28874736682019 @default.
• W2887473668 countsByYear W28874736682020 @default.
• W2887473668 countsByYear W28874736682021 @default.
• W2887473668 countsByYear W28874736682022 @default.
• W2887473668 countsByYear W28874736682023 @default.
• W2887473668 crossrefType "journal-article" @default.
• W2887473668 hasAuthorship W2887473668A5000413092 @default.
• W2887473668 hasAuthorship W2887473668A5001204975 @default.
• W2887473668 hasAuthorship W2887473668A5001816288 @default.
• W2887473668 hasAuthorship W2887473668A5002641296 @default.
• W2887473668 hasAuthorship W2887473668A5007455008 @default.
• W2887473668 hasAuthorship W2887473668A5011484481 @default.
• W2887473668 hasAuthorship W2887473668A5016568716 @default.
• W2887473668 hasAuthorship W2887473668A5028478747 @default.
• W2887473668 hasAuthorship W2887473668A5029183165 @default.
• W2887473668 hasAuthorship W2887473668A5038805449 @default.
• W2887473668 hasAuthorship W2887473668A5040846333 @default.
• W2887473668 hasAuthorship W2887473668A5049192558 @default.
• W2887473668 hasAuthorship W2887473668A5052880029 @default.
• W2887473668 hasAuthorship W2887473668A5064263842 @default.
• W2887473668 hasAuthorship W2887473668A5066068230 @default.
• W2887473668 hasAuthorship W2887473668A5071586460 @default.
• W2887473668 hasAuthorship W2887473668A5084619380 @default.
• W2887473668 hasAuthorship W2887473668A5088627335 @default.
• W2887473668 hasConcept C121608353 @default.
• W2887473668 hasConcept C126322002 @default.
• W2887473668 hasConcept C143998085 @default.
• W2887473668 hasConcept C2775949291 @default.
• W2887473668 hasConcept C2776256026 @default.
• W2887473668 hasConcept C2777701055 @default.
• W2887473668 hasConcept C2780057760 @default.
• W2887473668 hasConcept C71924100 @default.
• W2887473668 hasConceptScore W2887473668C121608353 @default.
• W2887473668 hasConceptScore W2887473668C126322002 @default.
• W2887473668 hasConceptScore W2887473668C143998085 @default.
• W2887473668 hasConceptScore W2887473668C2775949291 @default.
• W2887473668 hasConceptScore W2887473668C2776256026 @default.
• W2887473668 hasConceptScore W2887473668C2777701055 @default.
• W2887473668 hasConceptScore W2887473668C2780057760 @default.
• W2887473668 hasConceptScore W2887473668C71924100 @default.
• W2887473668 hasIssue "13_Supplement" @default.
• W2887473668 hasLocation W28874736681 @default.
• W2887473668 hasOpenAccess W2887473668 @default.
• W2887473668 hasPrimaryLocation W28874736681 @default.
• W2887473668 hasRelatedWork W1967103478 @default.
• W2887473668 hasRelatedWork W2032912323 @default.
• W2887473668 hasRelatedWork W2372561159 @default.
• W2887473668 hasRelatedWork W2375344515 @default.
• W2887473668 hasRelatedWork W2390152934 @default.
• W2887473668 hasRelatedWork W2516175431 @default.
• W2887473668 hasRelatedWork W2801647390 @default.
• W2887473668 hasRelatedWork W2900800946 @default.
• W2887473668 hasRelatedWork W2988890314 @default.
• W2887473668 hasRelatedWork W4288703684 @default.
• W2887473668 hasVolume "78" @default.
• W2887473668 isParatext "false" @default.
• W2887473668 isRetracted "false" @default.
• W2887473668 magId "2887473668" @default.
• W2887473668 workType "article" @default.